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abstract State newborn screening (NBS) programs routinely screen nearly all of the 4 million 
newborns in the United States each year for ~30 primary conditions and a number of 
secondary conditions. NBS could be on the cusp of an unprecedented expansion as a result 
of advances in whole-genome sequencing (WGS). As WGS becomes cheaper and easier 
and as our knowledge and understanding of human genetics expand, the question of 
whether WGS has a role to play in state NBS programs becomes increasingly relevant and 
complex. As geneticists and state public health officials begin to contemplate the technical 
and procedural details of whether WGS could benefit existing NBS programs, this is an 
opportune time to revisit the legal framework of state NBS programs. In this article, we 
examine the constitutional underpinnings of state-mandated NBS and explore the range 
of current state statutes and regulations that govern the programs. We consider the legal 
refinements that will be needed to keep state NBS programs within constitutional bounds, 
focusing on 2 areas of concern: consent procedures and the criteria used to select new 
conditions for NBS panels. We conclude by providing options for states to consider when 
contemplating the use of WGS for NBS.
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Praised as one of the most successful 
public health efforts of the 21st 
century, state newborn screening 
(NBS) programs routinely screen 
nearly all of the 4 million newborns 
in the United States each year for 
hereditary and congenital diseases. 
Originally established in 1963 to 
screen for phenylketonuria (PKU), 
the programs have expanded their 
scope substantially over the last 
50 years. State NBS programs 
now analyze newborns’ blood for 
~30 primary conditions and ≥25 
secondary conditions detectable in 
the process of confirming primary 
conditions. Improvements in 
genetic testing technology and in 
our understanding of the etiology of 
heritable disorders have contributed 
significantly to this expansion.
NBS could be on the cusp of an 
unprecedented expansion as a 
result of advances in whole-genome 
sequencing (WGS). As WGS becomes 
cheaper and easier and as our 
knowledge and understanding 
of human genetics expands, the 
question of whether WGS has a 
role to play in state NBS programs 
becomes increasingly relevant 
and complex. To date, much of the 
discussion surrounding the use of 
WGS in NBS programs has focused 
on feasibility, cost, reporting 
requirements, and the appropriate 
role of WGS in screening protocols. 
Less attention has been paid to the 
legal framework that would allow 
state agencies to mandate testing for 
a broader range of conditions.1–5
As geneticists and state public health 
officials begin to contemplate the 
technical and procedural details of 
whether WGS could benefit existing 
NBS programs, this is an opportune 
time to revisit the legal framework 
of state NBS programs. This article 
examines their constitutional 
underpinnings, explores the range of 
current state statutes and regulations 
that govern the programs, and 
provides options for states to 
consider when contemplating the use 
of WGS for NBS.
CONSTITUTIONAL FOUNDATIONS OF 
STATE NBS PROGRAmS
The state power to conduct public 
health programs, such as NBS, 
derives from 2 sources. First, 
under the Constitution, the Tenth 
Amendment reserves for the states 
the “police power.” This power allows 
states to implement programs to 
protect “the health, safety, morals 
and general welfare.”6 Second, a long-
standing common law doctrine called 
parens patriae permits states to make 
decisions for the health and well-
being of citizens who cannot speak 
on their own behalf. This power is 
often used to protect children and 
the mentally incapacitated.7 State-
mandated NBS involves both health 
and children, so the police power 
and the parens patriae power work 
in combination to justify the state’s 
ability to require screening.8
These 2 powers are not absolute, 
however. Any attempt by the 
government to mandate a medical 
procedure must be weighed against 
the individual’s constitutionally 
protected interests in personal 
autonomy and bodily integrity. 
The Supreme Court has repeatedly 
acknowledged that the Fourteenth 
Amendment protects an adult 
individual’s right to refuse unwanted 
medical interventions. The 
government can infringe on this 
fundamental right only if it has a 
compelling interest.9,10 Furthermore, 
the Fourteenth Amendment protects 
parents’ fundamental right to make 
decisions about their minor child’s 
welfare,11–13 including consenting to 
their medical treatment.
If a parent objects to state-imposed 
NBS, both the parent and the state 
would have strong constitutionally 
protected interests to support their 
claim. In a conflict, a court would 
have to balance these opposing 
interests to decide whether the state 
can mandate screening over parents’ 
objections. The parents could argue 
that the Fourteenth Amendment 
protects their right to refuse NBS 
on behalf of their child, based on 
the child’s right to bodily integrity 
and their right to make decisions on 
behalf of their child. But, “parents’ 
decision making for children does 
not have the same constitutional 
authority and protection against state 
intervention as does a competent 
adult’s personal health care decision 
making.”8 The Supreme Court 
has repeatedly held that the state 
authority to regulate children’s lives 
far exceeds its authority to regulate 
the lives of adults. Furthermore, the 
state’s police and parens patriae 
powers give the state substantial 
authority in matters relating to the 
health and well-being of children. 
Indeed, parental discretion is not 
unlimited, especially when it is 
used in ways that may endanger the 
child.8,14 Typically, states have been 
granted the opportunity to intervene 
when the parents’ decisions put the 
child at substantial risk of serious 
harm or illness.15 As a result, states 
have the ability to mandate NBS over 
parent objection only in instances 
where the screening will protect the 
child from serious harm.16–18
Although the constitutional 
requirements to mandate screening 
have not shifted significantly since 
NBS programs began, the factors 
deemed relevant to screening and the 
entities assessing which conditions 
should be included in state NBS 
programs have evolved substantially. 
NBS programs initially targeted a 
small set of genetic and metabolic 
conditions for which failure to make 
a timely diagnosis was associated 
with a high probability of serious, 
preventable harm to the child. In 
such cases, the balance of state 
and individual interests weighed 
heavily in favor of permitting 
states to require screening for all 
newborns. Furthermore, treatment 
was available to cure or stop the 
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progression of the disease for each of 
the initially selected severe childhood 
disorders. PKU is a classic example of 
a condition that justifies screening: It 
is not clinically detectable until it has 
caused irreversible harm, including 
severe mental retardation; treatment 
is simple (dietary management) and 
can prevent or mitigate symptoms; 
and the test is reliable, inexpensive, 
and minimally invasive and can be 
conducted early.19,20 The conditions 
screened for in the early years of NBS 
all shared these characteristics.
In the last 50 years, state NBS 
programs have grown substantially, 
both in the number of conditions 
screened for and their characteristics. 
A variety of forces drove this 
expansion. First, the development of 
tandem mass spectrometry allowed 
laboratories to simultaneously target 
several conditions, affordably and 
efficiently, by using the same dried 
blood spot used to test for PKU. 
Second, organizations such as Easter 
Seals and disease-specific patient 
advocacy groups, such as Hunter’s 
Hope Foundation, which advocated 
for Krabbe screening in New York, 
convinced state legislatures to 
mandate screening for specific 
conditions. Finally, the biggest single 
expansion in state screening panels 
came with the 2005 publication of 
a report by the American College 
of Medical Genetics and Genomics 
(ACMG) recommending a uniform 
screening panel.21 Ultimately adopted 
by the secretary of health and human 
services as a national standard for 
state programs, the recommended 
uniform screening panel (RUSP) 
originally consisted of 29 primary 
targets and 25 secondary conditions 
likely to be discovered during 
diagnostic confirmation of core test 
results.
In selecting the primary targets, the 
ACMG committee evaluated each 
of 84 candidate disorders against 
criteria pertaining to characteristics 
of the condition, the screening test 
for the condition, and available 
treatments. The scoring system 
favored conditions that were not 
likely to be detected clinically, 
for which early intervention was 
necessary to avoid serious harm, and 
that were inexpensive and simple to 
screen for, among other criteria.21 
The scoring system worked to 
justify screening for each condition 
on the panel based on the potential 
benefit to a child who received a 
positive diagnosis. However, the 
committee also strongly weighted 
the ability to screen for a condition 
via multiplex technology (ie, tandem 
mass spectrometry). The inclusion 
of multiplex capability in the initial 
selection criteria set an undesirable 
precedent for future evaluation 
because it is not related to the child’s 
benefit or the state interests that 
support use of the police or parens 
patriae powers.22 Technological 
feasibility and cost-effectiveness 
should be considered only after 
sufficient patient benefit has been 
established.
In 2008, the Newborn Screening 
Saves Lives Act transferred 
governance of the RUSP to the 
Advisory Committee on Heritable 
Diseases in Newborns and Children,23 
and since that time the committee 
has recommended inclusion of 
only 4 additional conditions.24 The 
committee recently augmented its 
criteria to take account of states’ 
readiness to implement new 
tests. Under the new criteria, the 
committee first weighs the net 
benefits of screening by analyzing the 
importance of the health outcomes 
to the population affected, the 
estimated health benefits that could 
result from testing, the possible 
harms associated with testing for 
the condition, and the efficacy and 
effectiveness of testing and follow-up 
as compared with usual clinical 
practice.25 Only after the committee 
has determined that screening for a 
particular condition will provide high 
or moderate certainty of significant 
benefit for newborns will feasibility 
and state readiness factor into a 
decision to recommend a condition to 
the RUSP. As a result, the committee’s 
new decision matrix appropriately 
addresses the constitutionally 
relevant factors before any 
consideration of implementation. 
Although the committee recommends 
conditions for inclusion in the RUSP 
from a national perspective, decisions 
about what conditions are screened 
for and NBS implementation occur 
entirely at the state level.
STATE ImPLEmENTATION OF NBS 
PROGRAmS
Laws governing NBS vary widely 
from state to state in several areas 
that will prove important especially 
in the context of WGS. First, states 
differ significantly in terms of their 
requirements for informed consent, 
the opportunity for parents to 
decline screening, and available 
exemptions (Table 1). Although all 
states allow medical exceptions to 
screening, little consensus exists 
on other exemptions. In 3 states, 
screening is mandatory, and the law 
does not permit parents to opt out 
for personal or religious reasons. In 
30 states, parents may opt out only 
on the basis of religion. Among states 
that permit only religious objections, 
the degree of proof parents must 
provide to validate their religious 
beliefs ranges from a sworn affidavit 
to a simple signature on a form. 
Some states require that parents be 
practicing members of an established 
church whose tenets forbid NBS. 
Fifteen states honor “personal” or 
philosophical objections in addition 
to religious objections. Several 
states, such as Arizona, California, 
and Delaware, make NBS an explicit 
exception to state laws generally 
requiring informed consent of 
patients or their parents for all 
medical procedures. Only 2 states, 
Maryland and Wyoming, expressly 
require the parents’ informed 
consent to conduct screening. Overall, 
the state laws reflect a general 
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consensus that the conditions tested 
for in the existing NBS programs do 
not require parental consent.
Furthermore, states do not require 
the public health agencies to provide 
parents with much information 
about NBS. Although most states 
have laws requiring NBS programs 
to provide some information to 
parents, few laws specify the 
information requirements in any 
depth. A handful of states require 
that parents receive information 
before the specimen is taken. Among 
states that require information to 
be given beforehand, some also 
require programs to inform parents 
of their right to object, or at least give 
them a reasonable opportunity to 
object, whereas others have no such 
requirement.
Beyond informed consent, the 
criteria states use for adding new 
conditions and tests to screening 
programs are highly relevant to the 
potential integration of WGS into 
NBS. A random sample of 24 states 
reveals wide variation (Table 2). 
Some states provide no criteria at 
all in their laws and regulations. 
Among states that do, no one set 
of criteria appears repeatedly. 
State laws often require that new 
conditions be severe or serious and 
treatable. They sometimes require 
a cost–benefit analysis. A few states 
mandate conformance with a uniform 
panel such as the RUSP or another 
set of recommendations from a 
professional body.
As for the screening tests, states 
may require that proposed tests 
be reliable, accurate, efficient, or 
consistent with accepted medical 
practices. A few states require new 
tests to be pilot-tested or already 
implemented in another jurisdiction. 
However, several states have no 
criteria in law pertaining to new test 
technologies.
Also striking is the absence of certain 
criteria that are especially important 
in the arena of NBS, criteria that 
relate to the constitutional and 
ethical permissibility of screening 
newborns without consent. Rarely 
do state laws expressly require that 
a new condition be one that is not 
detectable in clinical practice, or 
that has an early onset, or that needs 
treatment during the asymptomatic 
or newborn phase. Instead, state 
legislatures often mandate a specific 
panel of conditions and delegate to 
a public agency the power to expand 
the panel, with little or no guidance 
as to disease characteristics.
A final area of concern is the absence 
of special criteria or reporting 
requirements for secondary findings. 
Of the states we sampled, only 1, 
Massachusetts, made a distinction in 
law between primary and secondary 
conditions. This distinction takes on 
special significance in the context of 
WGS. With current test methods, for 
the most part secondary conditions 
are true incidental findings; the state 
laboratory reports a result, such 
as an elevated level of a particular 
analyte, to the pediatrician of record, 
and a specialist then conducts 
confirmatory testing and diagnosis, 
which sometimes reveals a condition 
other than the primary target. These 
secondary conditions are medically 
actionable, and there is little question 
TABLE 1  State Laws Governing Consent for NBS
Consent Policies Number of 
States
States
No exemption for religion or 
personal belief
3 AZ, NE, WV
Exemption for religion only 30 AL, CA, CO, CT, DE, GA, HI, ID, IL, IN, KS, KY, MA, ME, MO, 
MS, NJ, NY, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, 
WI, UT
 Must be members of 
established church that 
forbids NBS
9 CO, DE, ID, KY, NY, OR, TN, TX, UT
Exemption for religion or for 
personal or philosophical belief
15 AK, AR, FL, IA, LA, MI, MN, MT, NC, ND, NH, NM, NV, SD, VT
Informed consent required before 
screening
2 MD, WY
Must inform parent of right to 
object
3 MD, MN, WA
Must give parent reasonable 
opportunity to object
4 MD, MN, NJ, WI
This study examined statutes and regulations in each of the states. This chart does not reflect NBS program practices 
that deviate from state law. Additional research is needed to determine the extent to which laws reflect current practice.
TABLE 2  Examples of Criteria in State Law for Inclusion of Condition in NBS Panel
Criterion States
No criteria provided in law AR, NE
Condition must be severe or serious CA, CO, DE, GA, MA, MD, ME
Treatable, preventable, or ameliorable CA, CO, GA, ID, KS, MA, ME
Cost–benefit analysis required AZ, CO, MD, ME
Conformity with uniform panel or recommendations of a 
professional body
FL, GA, IA, KS, KY
Test must be reliable AL, AR, CO, CT, MA
Test must be accurate AL, CA
Test method must be efficient AR, CO, IL
Test must be consistent with accepted medical practices AK, CA, CO, FL, KS, MA
Pilot testing or use in another jurisdiction required before full 
implementation
CO, IL
No criteria in law for new test or technology AZ, CT, DE, IA, ID, WA
The 24 states sampled are AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, NE, TN, and WA. This 
study examined statutes and regulations in each of the states. This chart does not reflect NBS program practices that 
deviate from state law. Additional research is needed to determine the extent to which laws reflect current practice.
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that families would want to know 
about them. However, WGS can 
produce far more potential incidental 
findings, requiring more discernment 
on the part of states as to what 
conditions should be targeted and 
reported.1
Current state laws perhaps provide 
adequate protections for the range 
of conditions and test methods 
used in NBS today. In the future, 
however, if WGS is implemented 
in NBS programs, states will need 
protocols for determining when 
parental consent is required and far 
more robust criteria for choosing 
appropriate screening targets 
from among the myriad conditions 
detectable by WGS.
ThE ImPLICATIONS OF WGS FOR NBS
Currently, WGS is significantly more 
expensive and time-consuming 
than present NBS methods. At some 
point in the future, as genetic testing 
becomes cheaper and faster, it may 
become more efficient and cost-
effective than current methods. If 
that happens, WGS could be used 
to provide new parents with an 
expansive profile of their child’s 
genetic characteristics and risks. 
State NBS programs considering 
adopting WGS must be cognizant of 
the constitutional boundaries of their 
authority to test newborns without 
parental consent.
With the promise of WGS comes 
an ever-growing tension between 
a state’s ability to provide parents 
with potentially useful information 
soon after birth and its ability to 
mandate such screening. Along with 
immediately actionable results, WGS 
can find conditions that are not well 
understood, severe in prognosis, 
highly penetrant, and treatable 
in childhood. The state’s interest 
in screening for such conditions 
is weak and unlikely to outweigh 
the strongly protected rights of 
parents to make decisions for their 
children and to protect their bodily 
integrity. Conducting mandatory 
screening, without informed consent, 
for numerous conditions that are 
insufficient to justify the state’s 
intrusion on patient autonomy 
and parental rights will place state 
programs in untenable legal and 
ethical territory.
The constitution requires states to 
either make tests voluntary or justify 
mandating them. To incorporate WGS 
into mandatory NBS without running 
afoul of the constitution, states must 
be able to justify the screening in 
terms of the benefits to the child. The 
benefits must outweigh the risks. 
Even if WGS becomes cost-effective 
enough to be used routinely, it will 
still raise questions of accuracy and 
relevance to the child’s health. The 
risk of performing WGS on an infant 
stems not from the blood draw 
but from the discovery of genetic 
information that is potentially 
inaccurate, misleading, limited in its 
utility, or simply undesired by the 
parent. Gene sequencing may turn 
out to be a more cost-effective way 
to screen for the ~30 primary targets 
on the current RUSP, but it will also 
produce much more information. 
State NBS programs that seek to use 
WGS must decide what to do with any 
information they obtain from WGS 
that is not related to the primary 
targets.
OPTIONS FOR USING WGS
States will need criteria for 
determining which conditions can 
legally be targeted as part of the 
state’s primary panel and which 
require some form of parental 
consent. Furthermore, they will 
need criteria to address variants 
of unknown significance found 
in target genes and variants of 
known significance in nontarget 
genes. Without obtaining informed 
consent, states can use WGS to target 
or confirm primary conditions. 
However, consent is necessary 
before any genes not associated with 
primary conditions are analyzed. 
Consent is also necessary before 
any results are reported to families 
other than conditions that are either 
properly on a state’s primary panel 
or directly implicated by analyzing 
the gene for a primary condition. 
For instance, when a targeted gene 
sequence is probed for 1 mutation, 
another mutation of potential 
significance may be discovered. 
State programs should establish 
clear criteria for when a mutation 
discovered in such a manner should 
be reported.
The following are 3 general options 
for the use of WGS in NBS programs: 
1 without obtaining parental consent, 
1 with an opt-in feature, and 1 that 
would require full consent.
Option 1: Target or Confirm Only 
Primary Conditions, Discard 
Remaining Data
The first option states could pursue 
is to use WGS, without informed 
consent, to analyze the sequence 
for anomalies related to primary 
conditions on the screening panel, 
and then immediately discard 
the remaining sequence without 
analysis. States could use WGS as a 
first-tier or sole means of screening 
for primary conditions provided 
that it is a valid means of testing for 
those conditions. States could also 
use WGS as a second-tier test to 
confirm presumptive positive results 
obtained with other technologies. In 
this situation, public health agencies 
can screen without obtaining 
parental consent as long as the 
condition meets the legal criteria 
for being targeted by a screening 
program, and the laboratory analyzes 
only the appropriate genes and 
reports only the relevant results, 
ignoring and discarding all other 
data not uncovered by this process. 
Bypassing informed consent in this 
case should not breach constitutional 
protections because the state’s 
intrusion on the child’s autonomy 
and the parent’s right to control the 
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child’s health care is justified by the 
nature of the primary conditions.
The second-tier use of genetic 
sequencing has a parallel in state 
programs today. The California 
Newborn Screening Program screens 
for cystic fibrosis via a mutation 
panel of 40 known disease-causing 
mutations. Cystic fibrosis is a 
recessive disorder, which requires 2 
mutations for the disease phenotype 
to occur. When a newborn has ≥1 
known disease-causing mutations, 
the entire gene is sequenced, 
which sometimes reveals variants 
of unknown significance that can 
lead to a referral for additional 
evaluation. In this manner, California 
uses DNA testing to identify second 
mutations and confirm a positive 
result before reporting results to the 
family. Although California does not 
sequence the whole-genome as part 
of this protocol, it could do so legally 
without obtaining consent provided 
that it does not analyze irrelevant 
genes and does not keep extraneous 
data without consent.
Of course, this option makes sense 
only if the cost and efficiency of 
WGS improve enough to place it 
on par with the cost of sequencing 
individual genes. Even then, to many 
doctors, parents, and policymakers it 
may seem like a waste of resources 
to sequence an entire genome only 
to look at a small portion of it and 
discard the rest. If WGS does become 
a feasible technology for NBS, some 
families will want information about 
a wide range of conditions beyond 
primary targets.
Option 2: Target Only Primary 
Conditions and Give Parents the 
Option to Receive the Full Genomic 
Data in Raw Form
Instead of discarding the bulk of a 
newborn’s sequenced genomic data, 
as was proposed in option 1, the 
state could also use WGS as a first- or 
second-tier screen and grant parents 
the ability to receive their child’s 
raw sequence data. For parents who 
do not want a copy of their child’s 
sequence, the state should screen 
for primary conditions, as it does 
now, and then discard the sequence. 
However, for parents who want to 
know about additional variants or 
have their child’s sequenced genome 
transferred to their medical record 
for future use, states could enable 
parents to request the data. Providing 
the raw sequence data, in the absence 
of analysis, would necessarily require 
the parents to seek the services of 
a provider who could analyze and 
interpret it, thereby minimizing the 
risk of revealing unwanted genomic 
information to the parents or child 
without their express consent. If NBS 
programs integrate WGS, consent for 
raw data may be the most plausible 
option.
Ideally, parents should be informed 
of the opportunity to obtain the raw 
sequence data from the state or have 
it transferred to their pediatrician 
as a standard part of prenatal care. 
In preparing expectant mothers for 
labor and delivery, obstetricians 
often include a discussion about 
hospital protocols and what to expect 
throughout the process. As part of 
that conversation, the obstetrician 
or someone from his or her office 
could provide pregnant women with 
information from the state about the 
NBS program and the opportunity 
to choose to receive a copy of the 
sequenced, but largely unanalyzed, 
genomic data. States may want to 
give parents a time line to request 
the data before discarding it, perhaps 
for up to 1 year. State programs 
that choose to offer genomic data to 
parents should consider including 
information on genetic counseling 
resources, key factors to consider in 
deciding whether to retain the data, 
and the procedures and deadlines 
for requesting the data. States could 
also create or recommend decision 
aids to assist parents in weighing 
their options.26 For parents who do 
not receive this information during 
prenatal care, hospitals could provide 
such information before discharge, 
or pediatricians could provide it 
during the first year of pediatric care. 
This option retains parents’ ability 
to learn about their child’s genome 
on their own terms and avoids 
unnecessarily discarding a completed 
WGS.
Option 3: Obtain Informed Consent 
and Offer Parents Both the Genomic 
Sequence and Analysis
Alternatively, some states 
contemplating the use of WGS 
in NBS may decide to integrate 
informed consent into the program, 
abandoning mandatory screening 
entirely or requiring screening 
only for primary conditions while 
requesting consent to report all other 
results. This approach acknowledges 
that many parents will want access 
to and control of their children’s 
genomic data and that states may 
want to ensure the quality of analysis 
and interpretation provided to 
parents from its data.
However, obtaining a fully informed 
consent from parents for WGS 
analysis will prove challenging. 
Voluminous information about WGS 
and the targeted conditions would 
have to be condensed into easily 
comprehensible and digestible 
materials. Berg, Khoury, and Evans’s5 
proposal to streamline informed 
consent and genetic counseling by 
classifying genetic conditions into 
“predetermined clinically relevant 
bins” could be adapted for use in 
NBS. Researchers at the University of 
North Carolina are already working 
to classify conditions according to 
characteristics relevant to consent, 
resulting in such groupings as severe 
early childhood disorders, late onset 
disorders, disorders with moderate 
mental or physical symptoms, and 
predispositions to certain diseases.27 
The process of defining the bins for 
NBS informed consent would benefit 
from the expertise and cooperation 
of professional societies, such as 
ACMG, the National Society of Genetic 
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Counselors, and the American 
Academy of Pediatrics, as well as 
input from patient organizations 
regarding the most effective way of 
informing parents of their choices. 
Parents could receive standardized 
information on these panels of 
conditions, choose what genes 
should be analyzed and reported, 
and decide what to do with the 
balance of raw data. Furthermore, 
decision aids are being developed to 
help inform parents during prenatal 
counseling.28 Giving parents the 
relevant information and a range of 
options regarding genetic testing 
will protect their parental autonomy, 
child’s bodily integrity, and the 
child’s individual rights and preserve 
the constitutionality of the state 
program.
Providing for consent can help 
resolve more than just the 
constitutional problems. Many 
parents worry about retention and 
use of their children’s genetic data 
obtained through NBS. By educating 
parents during the prenatal period 
about the use of WGS in NBS and 
giving them control over reporting, 
retention, and use of the newborn 
bloodspots, states can also retain the 
trust of their citizens and avoid at 
least some of the expected political 
opposition.28
Any of the 3 options for incorporating 
WGS into NBS would bolster the 
program’s constitutionality. Option 
1 would incorporate WGS but not 
offer parents access to any findings 
beyond conditions currently tested 
for through NBS. Therefore, states 
should use WGS in this way only 
if it proves more cost-effective or 
accurate than existing options. 
Options 2 and 3 would offer parents 
substantially more information 
but would also require the state 
to establish a consent process for 
obtaining either the raw sequence 
data or more specific findings. 
Establishing such a process will 
require substantial input from a 
range of interested parties and 
experts. Although many of these 
discussions are already under way, 
much of the most challenging work 
remains.
CONCLUSIONS
In the future, as improvements in 
cost and efficiency make WGS more 
suitable for NBS, many families will 
no doubt want to take advantage of 
the rich information that WGS can 
provide. But integrating WGS into 
NBS programs raises substantial 
constitutional and statutory concerns 
that states must address. Depending 
on how it is used, WGS can generate 
numerous findings, only a small 
portion of which will be sufficiently 
important to justify mandatory 
testing and reporting. For any state 
choosing to incorporate WGS into its 
NBS program, transparency both in 
how it intends to use WGS and what 
it intends to do with the resulting 
sequence will be essential. State 
legislatures must set requirements 
for informed consent procedures 
that allow parents to meaningfully 
object or consent to DNA analysis 
and reporting of results. Given the 
dramatic number of incidental 
findings that could be revealed by 
WGS, it is crucial that states carefully 
distinguish between conditions 
that they can and cannot report on 
without parental consent. States must 
establish meaningful procedures 
to obtain informed consent from 
parents before revealing information 
beyond the primary conditions 
targeted by the NBS program. 
Without such protections, patients 
are at risk for experiencing harms 
that can result from receiving 
medical knowledge without sufficient 
context or support. Whether WGS 
becomes part of NBS, states need to 
clearly define and enforce criteria for 
determining which conditions will 
be targeted as part of the state NBS 
programs. State policymakers have a 
large role to play in the future of NBS, 
which will require them to carefully 
protect both the state’s interests and 
the fundamental rights of all citizens 
living in their state.
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